| Original language | English (US) |
|---|---|
| Pages (from-to) | 362-363 |
| Number of pages | 2 |
| Journal | The Lancet Infectious Diseases |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2012 |
| Externally published | Yes |
Bibliographical note
Funding Information:PGA has participated in expert testimony in two medicolegal suits about possible Lyme disease. RJD is part owner of and has stock in Biopeptides Corporation, has received grant support from the National Institutes of Health for the development of new serological assays for diagnosis of Lyme disease, and holds one patent and one patent pending for a peptide diagnostic agent for Lyme disease. JJH has served as an expert witness in several medicolegal cases concerning Lyme disease and has equity in Abbott, Bristol-Myers Squibb, Johnson and Johnson, and Merck; no products from these companies are referred to in this letter. RBN served as an expert witness in malpractice litigation involving Lyme disease and acted as a consultant for Guidepoint Global, providing advice about Lyme disease. SO has provided unpaid expert testimony to a fitness of practice hearing for the General Medical Council. EDS and GPW have been expert witnesses in malpractice cases involving Lyme disease and are unpaid board members of the America Lyme Disease Foundation. GPW has received research grants from the Centers for Disease Control and Protection, the National Institutes of Health, Immunetics, BioRad, DiaSorin, and Biomerieux; has equity in Abbott (not known to have any approved product for Lyme disease); and was an expert witness in a disciplinary action for the Missouri Board of Registration for the Healing Arts. The other authors declare that they have no conflicts of interest.